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Infections in Stem Ce[[ Transp[ant Recipients $29 
Conclusions: The tiketihood of being CMV seroposi- 
tire is higher in femates and order individuats. The 
risk has been decreasing over time both SCT pa- 
tients and their donors. The tiketihoods vary greatty 
between different countries. 
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Background: Infections are a reading cause of 
comptications in patients treated with high-dose 
chemotherapy and/or hematopoietic stem cett 
transptantation (HSCT) for hematotogicat matig- 
nancies. 
Methods: In a prospective observationat cohort 
study we recorded art btoodstream infections (BSI) 
and art new putmonary infittrates in patients hospi- 
tatized at the Hematotogic Reverse Isotation Unit of 
the University Hospitat Base[ from Jury 2003 untit 
June 2005. Putmonary infittrates were separated 
into bacteriat or fungat pneumonia according to 
microbiotogicat and radiotogicat findings. Invasive 
aspergillosis (IA) was ctassified as proven, proba- 
bte or possibte according to EORTC/MSG consensus 
definitions. 
Results: From Jury 2003 to June 2005, 160 pa- 
tients with 249 episodes of hospitatization were 
included. 91 (36%) episodes occurred during at- 
togeneic HSCT, 40 (16%) to autotogous HSCT and 
118 (47%) to induction/consotidation chemothera- 
pies. We noted 44 (18%) episodes of BSI (incidence 
13.8/1000 days of neutropenia), 53 (21%) episodes 
of pneumonia (incidence 17.3/1000 days of neu- 
tropenia) and 35 (14%) episodes of IA (26 possibte, 
5 probabte, 4 proven). IA occurred in 15/95 (16.5%) 
attogeneic HSCTs, in 16/118 (16%) chemotherapies 
and in onty 1/40 (2.6%) episodes of autotogous 
HSCT. The highest incidence of infectious compti- 
cations was seen in patients undergoing attogeneic 
HSCT (59/91, 65%), fottowed by patients receiving 
high-dose chemotherapies (58/118, 49%) and [ow- 
est after autotogous HSCT (12/40, 30%). Overatt 
in-hospitat mortatity was 13%; 12% in attogeneic 
HSCT, 8% in chemotherapies and 0% in autotogous 
HSCT. 
Conclusion: The incidence of BSI was tower 
than reported in the titerature, possibty retated 
to the routine use of chtorhexidine-suffadiazine- 
coated catheters. The incidence of pneumonia was 
higher probabty because of the regutarty performed 
CT scans. However, the IA rate was comparabte to 
the titerature. 
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Long-Term Suppressive Acyclovir (ACV) Use 
Reduces Varicella Zoster (VZV) Diseases 
and Emergence of ACV-Resistant Herpes 
Simplex Viruses (HSV) After Stem Cell 
Transplantation (HCT) 
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J. Heuget, L. Corey, M. Boeckh. Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA 
Background: One-yr ACV use effectivety reduces 
VZV disease at one yr after attogeneic HCT, but VZV 
disease continues to occur in patients on persistent 
immune suppression (Boeckh et at. Brood, 2006). 
Objectives: To determine the efficacy of two tong- 
term suppressive ACV regimens sequentiatty intro- 
duced at the Fred Hutchinson Cancer Research 
Center (FHCRC) in preventing VZV disease after 
attogeneic HCT. To evatuate the impact of tong- 
term suppressive ACV use on ACV-resistant HSV 
disease. 
Methods: Three cohorts of VZV seropositive T 
cett reptete attogeneic HCT recipients were ex- 
amined: cohort 1 (no ACV; before 1999, N=722), 
cohort 2 (ACV 800 mg or VACV 500 mg BID for 1 yr; 
1999-2002; N= 851 ), and cohort 3 (ACV/VACV as in 
cohort 2 ptus extended use in patients on contin- 
ued immunosuppressive drugs at 1 yr; 2002-2003, 
N = 402). The crude incidence rates of VZV disease 
in the 3 cohorts were catcutated at 1 yr and at 2yrs 
after HCT. Rate ratios (RR) were estimated by the 
Mantet-Haenszet person-time chi-square statistic. 
The probabitity of first VZV disease was evatuated 
using cumutative incidence estimates. The tog-rank 
test was used to assess the equatity of CI curves. In- 
cidence of taboratory proven HSV and ACV-resistant 
HSV disease was compared between the groups us- 
ing the fisher exact test. P vatues were two-sided. 
Results: At 1 yr after HCT, VZV disease decreased 
from 35.2 per 100 person-yrs in cohort 1 to 4.5 in 
cohort 2 and 1.4 in cohort 3; by two yrs after HCT, 
VZV disease decreased from 28 per 100 person- 
yrs in cohort 1 to 7.3 in cohort 2 and 3.6 in 
cohort 3. The incidence rate ratio (RR) comparing 
cohort 2 and cohort 3 to cohort 1 was 0.26 (95%CI 
0.20-0.34, p<0.001) and 0.12 (95%CI 0.07-0.21, 
p < 0.001), respectivety. RR comparing cohort 3 to 
cohort 2 was 0.48 (95%CI 0.28-0.84, p=0.008). 
The fraction of cases of VZV disease prevented 
exctusivety by ACV in cohort 2 and in cohort 3 was 
73% and 87% respectivety. One-yr (cohort 2) and 
